Similar articles

• Combining the anti-EGFR agent gefitinib with chemotherapy in non-small-cell lung cancer: how do we go from INTACT to impact?

  Baselga J. Baselga J. J Clin Oncol. 2004 Mar 1;22(5):759-61. doi: 10.1200/JCO.2004.12.903. J Clin Oncol. 2004. PMID: 14990627 No abstract available.
• [Gefitinib therapy in non-small-cell lung cancer].

  Jänne PA. Jänne PA. Duodecim. 2005;121(3):249-51. Duodecim. 2005. PMID: 15787283 Finnish. No abstract available.
• Implications of the Iressa Survival Evaluation in Lung Cancer trial and the future of gefitinib.

  Belani CP, Ramalingam S. Belani CP, et al. Clin Lung Cancer. 2005 Jan;6(4):203-4. Clin Lung Cancer. 2005. PMID: 15694010 No abstract available.
• Gefitinib in the treatment of advanced non-small-cell lung cancer.

  Reck M. Reck M. Expert Rev Anticancer Ther. 2009 Apr;9(4):401-12. doi: 10.1586/era.09.1. Expert Rev Anticancer Ther. 2009. PMID: 19374595 Review.
• Epidermal growth factor receptor inhibitors, gefitinib and erlotinib (Tarceva , OSI-774), in the treatment of bronchioloalveolar carcinoma.

  DeGrendele H. DeGrendele H. Clin Lung Cancer. 2003 Sep;5(2):83-5. doi: 10.1016/S1525-7304(11)70324-2. Clin Lung Cancer. 2003. PMID: 14596689 Review. No abstract available.